We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Lack of Cell Adhesion Protein Paves Way for Breast Cancer Development

By LabMedica International staff writers
Posted on 09 May 2012
A protein that is deficient in some types of breast tumors has been linked to the formation of desmosomes, complex protein structures that bind cells together into tissues and organs.

Desmosomes are molecular complexes of cell adhesion and linking proteins that attach cell surface adhesion proteins to intracellular keratin cytoskeletal filaments. More...
The cell adhesion proteins of the desmosome, desmoglein and desmocollin, are members of the cadherin family of cell adhesion molecules. They are transmembrane proteins that bridge the space between adjacent epithelial cells by way of homophilic binding of their extracellular domains to other desmosomal cadherins on the adjacent cell. Both have five extracellular domains, and have calcium-binding motifs.

A protein called Perp (TP53 apoptosis effector) had been shown previously to have a role in stratified epithelial integrity and cell-cell adhesion by promoting desmosome assembly. In the current study, investigators at Stanford University (Palo Alto, CA, USA) sought to explain why mice genetically engineered to lack the gene for Perp production suffered from severe blistering of the epidermis and oral mucosa and how this type of inflammatory response was linked to formation of breast tumors.

They reported in the April 20, 2012, online edition of the journal Breast Cancer Research that Perp protein was expressed in the mammary epithelium, where it co-localized with desmosomes. Perp loss affected mammary epithelial homeostasis by causing the accumulation of inflammatory cells around mature mammary epithelium. Reduced Perp expression was detected in many human breast cancer cell lines compared to untransformed cells, and Perp-deficiency promoted the development of mouse mammary cancer.

Senior author Dr. Laura Attardi, associate professor of radiation oncology at Stanford University, said, “Perp deficiency caused defects in desmosomal protein expression in breast epithelial cells. At the same time, there was an enhanced inflammatory response in the breast tissue, and tumors tended to develop more quickly. We also found in the lab that breast cancer cells had abnormally low levels of Perp.”

Related Links:
Stanford University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Platelet Function Analyzer
PL-12
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.